HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

Simple item page
dc.contributor.authorVolk, JEen_ZA
dc.contributor.authorHessol, NAen_ZA
dc.contributor.authorGray, GEen_ZA
dc.contributor.authorKublin, JGen_ZA
dc.contributor.authorChurchyard, Gen_ZA
dc.contributor.authorMlisana, Ken_ZA
dc.contributor.authorNchabeleng, Men_ZA
dc.contributor.authorBuchbinder, SPen_ZA
dc.contributor.authorBekker, Len_ZA
dc.date.accessioned2015-11-23T11:39:07Z
dc.date.available2015-11-23T11:39:07Z
dc.date.issued2012en_ZA
dc.description.abstractWorldwide, many adolescents, especially women, acquire HIV before age 18. Yet to date, no HIV vaccine trials have enrolled adolescents. Reasons for excluding adolescents from these trials include regulations protecting vulnerable subjects and concerns regarding informed consent, social harms, adverse events, and loss to follow-up.en_ZA
dc.identifier.apacitationVolk, J., Hessol, N., Gray, G., Kublin, J., Churchyard, G., Mlisana, K., ... Bekker, L. (2012). HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials. <i>Retrovirology</i>, http://hdl.handle.net/11427/15226en_ZA
dc.identifier.chicagocitationVolk, JE, NA Hessol, GE Gray, JG Kublin, G Churchyard, K Mlisana, M Nchabeleng, SP Buchbinder, and L Bekker "HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials." <i>Retrovirology</i> (2012) http://hdl.handle.net/11427/15226en_ZA
dc.identifier.citationVolk, J. E., Hessol, N. A., Gray, G. E., Kublin, J. G., Churchyard, G., Mlisana, K., ... & Bekker, L. (2012). HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials. Retrovirology, 9(Suppl 2), P131.en_ZA
dc.identifier.ris TY - Journal Article AU - Volk, JE AU - Hessol, NA AU - Gray, GE AU - Kublin, JG AU - Churchyard, G AU - Mlisana, K AU - Nchabeleng, M AU - Buchbinder, SP AU - Bekker, L AB - Worldwide, many adolescents, especially women, acquire HIV before age 18. Yet to date, no HIV vaccine trials have enrolled adolescents. Reasons for excluding adolescents from these trials include regulations protecting vulnerable subjects and concerns regarding informed consent, social harms, adverse events, and loss to follow-up. DA - 2012 DB - OpenUCT DO - 10.1186/1742-4690-9-S2-P131 DP - University of Cape Town J1 - Retrovirology LK - https://open.uct.ac.za PB - University of Cape Town PY - 2012 T1 - HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials TI - HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials UR - http://hdl.handle.net/11427/15226 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/15226
dc.identifier.urihttp://dx.doi.org/10.1186/1742-4690-9-S2-P131
dc.identifier.vancouvercitationVolk J, Hessol N, Gray G, Kublin J, Churchyard G, Mlisana K, et al. HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials. Retrovirology. 2012; http://hdl.handle.net/11427/15226.en_ZA
dc.language.isoengen_ZA
dc.publisherBioMed Central Ltden_ZA
dc.publisher.departmentDesmond Tutu HIV Centreen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licenseen_ZA
dc.rights.holder2012 Volk et al; licensee BioMed Central Ltd.en_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_ZA
dc.sourceRetrovirologyen_ZA
dc.source.urihttp://www.retrovirology.com/en_ZA
dc.subject.otherHIV vaccine trialsen_ZA
dc.subject.otheradolescentsen_ZA
dc.subject.othervulnerable subjectsen_ZA
dc.titleHIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trialsen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Volk_HIV_vaccine_trial_safety_2012.pdf
Size:
129.37 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles